SCHEMBL4276945

SCHEMBL4276945

Cc1ccc(-c2ccc[c]c2Cl)cc1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.40
ESR2 Q92731 2/20 0.37
MCL1 Q07820 1/20 0.36
TSHR P16473 1/20 0.36
CASP1 P29466 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
G6PD P11413 1/20 0.35
CYP2C9 P11712 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
ALOX12 P18054 1/20 0.35
MAPK1 P28482 1/20 0.35
CYP2C19 P33261 1/20 0.35
CCR6 P51684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4276821 0.83 APP (0.42) APPESR2TSHRALDH1A1CYP3A4
SCHEMBL4280979 0.80 HSD17B1 (0.45) APPESR2PTGS1ESR1HSD17B1
SCHEMBL4280909 0.78 ALDH1A1 (0.41) APPMCL1KDM4EALDH1A1CYP3A4
SCHEMBL4282490 0.78 MKNK1 (0.47) APPMCL1TSHRCASP1KDM4E
SCHEMBL4274645 0.77 PLA2G7 (0.37) ESR2KDM4EALDH1A1CYP3A4HPGD
SCHEMBL4275992 0.76 HSD17B1 (0.50) ESR2TSHRCYP1A2CYP3A4CYP2D6
SCHEMBL21317795 0.75 DHODH (0.43) APPKDM4ETLR8KDM1AKMT2A
SCHEMBL4277811 0.75 PTGES2 (0.39) APPPTGS1
SCHEMBL4282096 0.75 MEN1 (0.41) MCL1ALDH1A1HPGDKMT2A
SCHEMBL4277908 0.75 PDK2 (0.49) TSHRKDM4ECYP1A2CYP2D6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2397462-A2 Compounds, compositions and methods of treatment for heart failure Cytokinetics, Inc. (US) 2011-12-21 EP disclosed
US-20090176307-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-07-09 US disclosed
US-7491826-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2009-02-17 US disclosed
US-7399866-B2 Compounds, compositions, and methods CYTOKINETICS, INC. (US) 2008-07-15 US disclosed
US-20060241110-A1 Compounds, compositions, and methods CYTOKINETICS, INCORPORATED 2006-10-26 US disclosed
US-20050159416-A1 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2005-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241110-A1 Compounds, compositions, and methods TNNI3, TNNT2, TNNC1 APP 4629/4885ESR2 3909/4885MCL1 2808/4885
US-20050159416-A1 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 APP 4587/4885ESR2 3756/4885MCL1 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.